Financial Performance - The estimated net profit for the first half of 2024 is projected to be between 20,762.88 million RMB and 23,729.01 million RMB, representing a year-on-year growth of 40.00% to 60.00% compared to 14,830.63 million RMB in the same period last year [4]. - The net profit after deducting non-recurring gains and losses is expected to be between 21,214.78 million RMB and 22,982.67 million RMB, reflecting a significant increase of 140.00% to 160.00% from 8,839.49 million RMB in the previous year [4]. - The company's main business revenue is steadily increasing, and operational efficiency is further improving, leading to stable growth in performance [6]. Product and Market Strategy - The company has five listed drugs, four of which are included in the national medical insurance catalog, contributing to the revenue growth [5]. - The company is actively conducting post-marketing clinical research to expand indications and enhance product differentiation advantages [5]. - Continuous efforts are being made to strengthen market promotion and improve drug market share across hospitals and pharmacies nationwide [6]. Caution and Disclosure - The financial data presented is preliminary and has not been audited by the accounting firm, with detailed financial information to be disclosed in the 2024 semi-annual report [5]. - Investors are advised to be cautious and aware of investment risks based on the preliminary nature of the performance forecast [6].

Financial Performance - Revenue in 2023 increased by 3.35% to 2,456,196,486.62 yuan compared to 2022[10] - Net profit attributable to shareholders surged by 139.33% to 348,032,472.42 yuan in 2023[10] - Operating cash flow grew significantly by 198.05% to 914,227,977.50 yuan in 2023[10] - Basic earnings per share rose by 137.14% to 0.83 yuan in 2023[10] - Total assets increased by 15.64% to 9,146,908,395.53 yuan at the end of 2023[10] - Q2 2023 revenue was the highest at 782,259,420.96 yuan among all quarters[11] - Q3 2023 net profit attributable to shareholders reached 156,386,574.59 yuan, the highest quarterly figure[11] - Revenue for 2023 reached 24.56 billion yuan, a year-on-year increase of 3.35%[39] - Net profit attributable to shareholders was 348.03 million yuan, up 139.33% year-on-year[39] - Non-GAAP net profit was 262.85 million yuan, a significant increase of 768.85% year-on-year[39] - Operating cash flow surged to 914.23 million yuan, up 198.05% year-on-year[41] - Total revenue for 2023 reached 2,456,196,486.62 yuan, a year-on-year increase of 3.35%[56] - Pharmaceutical manufacturing accounted for 100% of total revenue, with drug sales contributing 98.40%[56] - Domestic sales accounted for 99.96% of total revenue, with a year-on-year increase of 3.32%[56] - Gross profit margin for pharmaceutical manufacturing was 83.53%, a decrease of 5.16% compared to the previous year[57] - Sales volume increased by 2.52% to 3,047,651 boxes, while production volume decreased by 15.71% to 3,806,830 boxes[58] - The top five customers accounted for 61.45% of total sales, with the largest customer contributing 31.62%[61] - The top five suppliers accounted for 42.23% of total procurement, with the largest supplier contributing 17.17%[62][63] - Sales expenses increased by 9.61% to RMB 853.89 million in 2023 compared to RMB 779.06 million in 2022[64] - Management expenses decreased by 42.49% to RMB 261.76 million in 2023 due to reduced equity incentive costs[64] - Financial expenses decreased by 77.45% to RMB 39.59 million in 2023 due to reduced interest expenses[64] - R&D expenses decreased by 8.54% to RMB 640.14 million in 2023 compared to RMB 699.90 million in 2022[64] - Operating cash flow increased by 198.05% to 914,227,977.50 yuan, driven by higher cash inflows from drug sales[68] - Investment cash flow net outflow increased by 13.68% to -1,505,452,905.04 yuan, mainly due to the purchase of long-term assets and equity investments[68] - Financing cash flow net inflow decreased by 35.40% to 608,193,350.56 yuan, despite a 79.00% increase in cash inflows from financing activities[68] - Net cash and cash equivalents increased by 134.12% to 20,712,054.82 yuan[68] - Non-operating income accounted for 19.12% of total profit, primarily from compensation payments[70] - Long-term loans increased by 11.56% to 1,816,000,000.00 yuan, reflecting new bank loans during the reporting period[71] - Intangible assets increased by 5.84% to 1,943,510,385.64 yuan, mainly due to the transfer of development costs for newly approved drugs[71] - Overseas assets accounted for 26.25% of the company's net assets, with Xcovery Holdings, Inc. being the largest contributor[72] - The fair value of other equity instrument investments increased by 41,845,298.27 yuan, reaching 1,006,597,002.32 yuan at the end of the period[73] - Total investment during the reporting period increased by 8.30% to 1,705,971,266.15 yuan[74] - The company invested a total of 1,116,240,904.06 yuan in significant equity investments during the reporting period, with a total investment loss of -21,721,933.08 yuan[75] - The company invested 716,490,862.42 yuan in Xcovery Holdings, Inc., holding a 98.44% stake, resulting in a loss of -19,696,491.56 yuan[75] - The company invested 249,750,000.00 yuan in Hangzhou Beicheng Venture Capital Partnership, holding a 49.95% stake, resulting in a loss of -2,025,441.52 yuan[75] - The company invested 150,000,041.64 yuan in Beijing Mabworks Biotech Co., Ltd., holding a 2.91% stake[75] - The company invested a total of 589,730,362.09 yuan in significant non-equity investments during the reporting period, with a cumulative actual investment of 1,958,290,885.25 yuan[76] - The DreamWorks Phase II project has a cumulative investment of 1,313,872,501.95 yuan, with a progress rate of 72.99%[76] - The Shengzhou Innovative Drug Industrialization Base project has a cumulative investment of 644,418,383.30 yuan, with a progress rate of 65.76%[76] - The company's securities investment in AGENUS resulted in a loss of -52,907,243.50 yuan, with an ending book value of 28,595,124.38 yuan[77] - The company invested 150,000,041.64 yuan in Beijing Mabworks Biotech Co., Ltd. through a private placement, holding 2,095,558 shares[78] - The company's total raised funds amounted to 1,001,999,913.43 yuan, with a net amount of 995,405,374.70 yuan, and a cumulative usage of 68,991.37 million yuan[79] - The company used up to 300 million yuan of idle raised funds to temporarily supplement working capital, with a usage period not exceeding 12 months, and the full amount was returned to the raised funds special account by December 9, 2023[80] - As of December 31, 2023, the balance of idle raised funds used to temporarily supplement working capital was 260 million yuan[80] - The new drug R&D and R&D equipment upgrade project had a total investment commitment of 742 million yuan, with 58.83% (436.51 million yuan) invested by the end of the reporting period[81] - The supplementary working capital project had a total investment commitment of 260 million yuan, with 100% (253.41 million yuan) invested by the end of the reporting period[81] - The CM082 combined with JS001 for mucosal melanoma treatment clinical phase III project was suspended due to insufficient clinical advantages and inability to gain commercial competitive advantage in the current market environment[81] - The company used 176.58 million yuan of raised funds to replace pre-invested self-raised funds in the fundraising projects and paid issuance costs[81] - As of December 31, 2023, the unused raised funds were stored in the company's raised funds special account, with a balance of 260 million yuan temporarily supplementing working capital[82] - BPI-16350 project received RMB 127.5057 million in funding for Phase III clinical trials targeting HR-positive/HER2-negative advanced breast cancer[83][84] - The investment progress for BPI-16350 reached 62.90% with RMB 80.2009 million cumulatively invested by the end of the reporting period[83] - Hydrochloric acid ensartinib capsule project received RMB 60 million for Phase III clinical trials targeting ALK-positive NSCLC postoperative adjuvant treatment[83][84] - The investment progress for hydrochloric acid ensartinib capsule project reached 21.49% with RMB 12.8927 million cumulatively invested by the end of the reporting period[83] - X-396 project funding was reduced as it completed Phase III clinical trials and received approval for market launch[84] - CM082 combined with JS001 project funding was reduced due to insufficient clinical advantages and lack of commercial competitiveness[84] - MIL60 project funding was reduced as it completed Phase III clinical trials and received approval for market launch[84] - Total adjusted funding for new drug R&D projects amounted to RMB 187.5057 million[83] - Xcovery Holdings, Inc., a subsidiary, reported a net loss of RMB 199.3499 million[85] Product Portfolio and R&D - The company's main products include "Kemena" (Icotinib Hydrochloride Tablets), "Beimena" (Ensartinib), "Beianting" (Bevacizumab Injection), "Saimena" (Befotertinib Mesylate Capsules), and "Fumena" (Vorolanib Tablets)[4] - The company's Beijing and Hangzhou R&D centers are subsidiaries focused on new drug development[4] - The company's main business is the development and production of anti-tumor drugs, including small molecule and large molecule drugs[4] - The company's products are mainly used for the treatment of non-small cell lung cancer (NSCLC) and other cancers[4] - The company has successfully commercialized five new drugs, including Kaimeina, Beimeina, and Saimeina, which have become new revenue growth drivers[22] - The company has established a strong position in the lung cancer treatment field, with Kaimeina being the first domestically developed small molecule lung cancer targeted drug in China[21] - The company has also achieved a breakthrough in the kidney cancer treatment field with the launch of Fumeina, the first domestically developed anti-angiogenic drug in China[21] - The company's R&D pipeline focuses on unmet clinical needs in the field of malignant tumor treatment, particularly lung cancer[21] - The company's strategy includes academic promotion and real-world research to meet the treatment needs of experts and patients[21] - The company aims to build differentiated product advantages and promote more products to achieve successful commercialization[21] - Kemena (Icotinib) achieved a median DFS of 47.0 months vs. 22.1 months in the chemotherapy group for II-IIIA stage NSCLC patients with EGFR mutations[25] - Kemena reduced the risk of disease recurrence by 77% in completely resected IB stage NSCLC patients compared to the observation group[25] - Kemena's 3-year DFS rate was 63.9% vs. 32.5% in the chemotherapy group for II-IIIA stage NSCLC patients[25] - Bemnax (Ensartinib) showed a median PFS of 41.5 months in the overall population and 47.1 months in the non-brain metastasis population for ALK-positive NSCLC[24] - Bemnax's new drug application for first-line treatment of ALK-positive NSCLC was accepted by the US FDA[24] - Saimena (Furmonertinib) achieved a median PFS of 22.1 months in first-line treatment and 16.6 months in second-line treatment for EGFR-mutated NSCLC[24] - Saimena's median OS in second-line treatment reached 31.5 months, with an ORR of 92.3% in patients with baseline brain metastases[24] - Fumena (Fruquintinib) combined with everolimus achieved a median PFS of 10 months and a median OS of 30.4 months in advanced RCC patients[24] - Kemena has been involved in over 100 clinical studies and published 259 SCI papers with a total impact factor of 1,086.97[25] - Kemena was included in the National Reimbursement Drug List (NRDL) for all its approved indications[25] - Envonalkib (Bemena) has achieved a median PFS of 41.5 months in the Asian population, with a 4-year OS rate of 75.7% in the baseline non-brain metastasis group[27] - Envonalkib (Bemena) demonstrated a median PFS of 23.9 months in patients with baseline brain metastasis[27] - Envonalkib (Bemena) showed a median OS of 42.8 months in patients with advanced crizotinib-resistant NSCLC[27] - Envonalkib (Bemena) has published 64 articles with a total impact factor of nearly 400 points[27] - Envonalkib (Bemena) has completed enrollment for Phase II-IIIB in postoperative adjuvant therapy trials in China[26] - Envonalkib (Bemena) has submitted a new drug application for first-line treatment to the US FDA in March 2024[26] - Bevacizumab (Beianting) demonstrated an ORR of 48.6% at 12 weeks, equivalent to Avastin[28] - Bevacizumab (Beianting) has published 3 SCI papers with a total impact factor of 24.23 points[29] - BPI-D0316 (Saimeina) is a novel third-generation EGFR-TKI with independent intellectual property rights[30] - Saimena (Befotertinib) achieved a median PFS of 22.1 months in the IBIO-103 study, significantly higher than the 13.8 months in the Icotinib group[31] - Saimena's median PFS for patients with baseline brain metastasis was 19.4 months, compared to 13.7 months in the Icotinib group[31] - Saimena has been included in the National Reimbursement Drug List and has published 5 SCI papers with a total impact factor of 116.66[31] - Fumena (Vorolanib) combined with Everolimus showed a median PFS of 10.0 months, significantly better than the 6.4 months in the Everolimus monotherapy group[33] - Fumena combined with Everolimus achieved an ORR of 24.8%, significantly higher than the 8.3% in the Everolimus monotherapy group[33] - Fumena has published 17 SCI papers with a total impact factor of 74.06 and has been presented at international conferences[33] - EYP-1901, a sustained-release formulation of Vorolanib, reduced injection frequency by 89% and 85% in the 2mg and 3mg dose groups, respectively[33] - 65% and 64% of patients in the EYP-1901 2mg and 3mg dose groups did not require anti-VEGF rescue therapy for six months[33] - The company has established a leading domestic R&D system with centers in Beijing and Hangzhou, focusing on unmet clinical needs[35] - The company adheres to GMP standards throughout the entire production process, ensuring stable product quality[37] - R&D investment in 2023 was 1.00 billion yuan, accounting for 40.80% of revenue[41] - Kaimeina (凯美纳) extended its product lifecycle with stable sales, supported by strong clinical data[40] - Beimeina (贝美纳) saw rapid sales growth after being included in the National Reimbursement Drug List (NRDL) in 2023[40] - New products Saimeina (赛美纳) and Fumeina (伏美纳) were approved and included in the NRDL, contributing to revenue growth[40] - The company has 5 marketed products, with 4 included in the NRDL, diversifying revenue sources[48] - Strategic collaborations with companies like TianGuangShi and EYPT enriched the R&D pipeline[45] - R&D investment in 2023 reached RMB 10,020.505 million, accounting for 40.80% of total revenue, driving pipeline growth and achieving milestones[49] - 5 products are now on the market, with 4 included in the National Reimbursement Drug List (NRDL)[49] - BPI-16350 Phase III clinical study completed patient enrollment in April 2023, showing a confirmed ORR of 60.5% with good safety[49] - 10 drug candidates/indications received clinical trial approvals in 2023, including TEAD inhibitor BPI-460372 approved for clinical studies in both China and the US[49] - CFT8919 exclusive rights in China secured with a $10 million upfront payment, and $25 million invested in C4T for 5,567,928 shares[51] - RMB 21 million invested in Hangzhou Guoshun Jianheng Venture Capital Partnership, with the company contributing RMB 4 million (19.05%)[51] - Production of all batches in 2023 achieved a 100% qualification rate, ensuring stable supply for commercial and clinical use[52] - BPI-442096, BPI-371153, BPI-361175, BPI-452080, BPI-460372, and BPI-21668 clinical trial drug supplies were delivered as planned[53] - Ensartinib (ALK inhibitor) NDA for NSCLC treatment accepted by the US FDA, currently under review[54] - Caimena and Baimena maintained in the NRDL, while Samena and Fumena were newly included in 2023[54] - The company's main products include Icotinib Hydrochloride Tablets, Ensartinib Hydrochloride Capsules, Befotertinib Mesylate Capsules, and Vorolanib Tablets, all of which are protected by patents until at least 2027[55] - The company has multiple R&D projects in Phase III clinical trials, including BPI-16350 and BPI-D0316, which are expected to contribute to future revenue growth[65] - The company decided to suspend the development of BPI-43487 and BPI-421286 due to insufficient clinical advantages[66] Corporate Governance and Shareholder Information - The company's profit distribution plan for 2023 is to distribute a cash dividend of 1.7 yuan per 10 shares (tax included) based on 418,485,885 shares[3] - The company's registered address was changed to No. 355 Xingzhong Road, Economic and Technological Development Zone, Linping District, Hangzhou, Zhejiang Province on December 12, 2023[6] - The company's stock code is 300558, and its legal representative is Ding Lieming[6] -

Financial Performance - The company's revenue for Q1 2024 reached ¥735,775,468.80, representing a 38.40% increase compared to ¥531,618,547.85 in the same period last year[5] - Net profit attributable to shareholders was ¥98,140,741.56, a significant increase of 90.95% from ¥51,396,813.71 year-over-year[5] - The net profit after deducting non-recurring gains and losses surged by 390.39% to ¥89,562,834.38, compared to ¥18,263,590.71 in the previous year[5] - Basic and diluted earnings per share both rose to ¥0.23, reflecting a 91.67% increase from ¥0.12[5] - Operating profit for the quarter was ¥108,359,629.25, compared to ¥4,863,487.35 in Q1 2023, indicating a substantial improvement[20] - The company reported a total comprehensive income of ¥241,283,970.75, significantly higher than ¥11,728,582.69 in the previous year[21] Cash Flow and Assets - Operating cash flow net amount increased by 79.12% to ¥247,235,603.12, up from ¥138,024,453.30 in the same quarter last year[5] - Cash inflow from operating activities totaled ¥868,051,394.75, an increase from ¥675,281,814.25 in Q1 2023[22] - Total current assets decreased from CNY 1,525,880,626.51 to CNY 1,291,522,377.58, a reduction of approximately 15.3%[18] - Cash and cash equivalents decreased from CNY 751,996,914.50 to CNY 554,020,499.69, a decline of about 26.3%[18] - Total assets at the end of the reporting period were ¥9,326,460,058.88, a 1.96% increase from ¥9,146,908,395.53 at the end of the previous year[5] - The cash inflow from financing activities was 308,600,000.00 CNY, significantly lower than 1,138,995,335.39 CNY in the previous year, a decrease of about 72.9%[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 27,919, with the top ten shareholders holding significant stakes[8] - Shareholders' equity attributable to the parent company increased by 5.16% to ¥5,522,175,127.32 from ¥5,251,077,081.90[5] - The company’s major shareholders include Ningbo Kaiming Investment Management Partnership, holding 80,064,000 shares, which is 21.74% of the total shares[10] Research and Development - R&D investment for Q1 2024 was 209.30 million RMB, accounting for 28.44% of operating revenue[13] - The company received FDA acceptance for the market application of its drug, Baimena, which is expected to be the first lung cancer targeted innovative drug developed by a Chinese pharmaceutical company to be launched globally[14] - Clinical trial approval notifications were received for the Pan-EGFR inhibitor BPI-520105 and the IDH1/IDH2 dual inhibitor BPI-221351[14] - The company is actively monitoring the progress of EYP-1901's clinical research abroad and coordinating domestic clinical research efforts[15] - EYP-1901 shows promising future treatment potential for wet AMD, with ongoing clinical trials for NPDR and DME[15] Operational Strategy - The company continues to optimize operations based on market competition and business development needs[13] - The company plans to continue its new drug development projects and market expansion strategies[13] - The company has ongoing strategic collaborations and investments, including the introduction of project CFT8919[17] Liabilities and Expenses - Total liabilities decreased from CNY 3,795,434,736.73 to CNY 3,713,620,126.31, a reduction of approximately 2.2%[19] - Sales expenses rose by 49.54% to ¥230,482,714.67, primarily due to increased costs associated with new product promotions[7] - Research and development expenses were ¥152,750,433.40, a decrease of 12.9% from ¥175,355,803.09 in the previous year[20] - The total cash outflow for employee compensation was 213,183,145.78 CNY, up from 199,114,465.21 CNY, marking an increase of approximately 7.4%[23] - The company paid taxes amounting to 25,301,455.53 CNY, which is an increase from 15,855,962.13 CNY, representing a growth of about 59.5%[23]

证券代码：300558 证券简称：贝达药业 公告编号：2023-100 贝达药业股份有限公司 3、公司向中国结算深圳分公司就核查对象在自查期间买卖公司股票情况 进行了查询确认，并由中国结算深圳分公司出具了《信息披露义务人持股及股 份变更查询证明》及《股东股份变更明细清单》。 二、核查对象买卖公司股票的情况说明 根据中国结算深圳分公司出具的《信息披露义务人持股及股份变更查询证 明》及《股东股份变更明细清单》，自查期间公司内幕信息知情人和激励对象 买卖公司股票情况如下： 关于 2023 年限制性股票激励计划内幕信息知情人及激励对象 买卖公司股票情况的自查报告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 贝达药业股份有限公司（以下简称"公司"）于 2023 年 11 月 17 日召开 第四届董事会第十次会议、第四届监事会第八次会议，审议通过了《关于<贝 达药业股份有限公司 2023 年限制性股票激励计划（草案）>及其摘要的议案》 等议案 ， 具 体 内 容 详 见 公 司 于 2023 年 11 月 18 日 在 巨 潮 资 讯 网 （www.cninfo.co ...

国浩律师（杭州）事务所 贝达药业 2023 年第一次临时股东大会法律意见书 国浩律师（杭州）事务所 关于 贝达药业股份有限公司 2023 年第一次临时股东大会的法律意见书 致：贝达药业股份有限公司 国浩律师（杭州）事务所（以下简称本所）接受贝达药业股份有限公司（以 下简称公司）的委托，指派律师出席公司 2023 年第一次临时股东大会（以下简 称本次股东大会），并依据《中华人民共和国公司法》（以下简称《公司法》）、 《中华人民共和国证券法》（以下简称《证券法》）、中国证券监督管理委员会 （以下简称中国证监会）发布的《上市公司股东大会规则》（2022 年修订）（以 下简称《股东大会规则》）、《上市公司治理准则》（2018 年修订）（以下简 称《治理准则》）和深圳证券交易所发布的《深圳证券交易所上市公司股东大会 网络投票实施细则（2020 年修订）》（以下简称《网络投票实施细则》）等法 律、行政法规、规范性文件及现行有效的《贝达药业股份有限公司章程》（以下 简称《公司章程》）、《贝达药业股份有限公司股东大会议事规则》（以下简称 《股东大会议事规则》）的规定，就本次股东大会的召集、召开程序、出席大会 人员资格、会议表 ...

证券代码：300558 证券简称：贝达药业 公告编号：2023-101 贝达药业股份有限公司 关于 CFT8919 片获得临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 今日，贝达药业股份有限公司（以下简称"公司"）收到国家药品监督管 理局（以下简称"NMPA"）签发的《药物临床试验批准通知书》（通知书编 号：2023LP02450、2023LP02451），公司从 C4 Therapeutics, Inc.（NASDAQ:CCCC， 以下简称"C4T"）引进的 CFT8919 片"拟用于携带表皮生长因子受体（EGFR） 突变的局晚期或晚期非小细胞肺癌患者"的药品临床试验（以下简称"该临床试 验"）申请已获得 NMPA 批准开展，现将具体情况公告如下： 一、该临床试验的基本情况 产品名称：CFT8919 片 受理号：JXHL2300237；JXHL2300238 通知书编号：2023LP02450；2023LP02451 注册代理机构：贝达药业股份有限公司 结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2023 年 09 ...

贝达药业股份有限公司 2023 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有出现否决议案的情形； 2、本次股东大会没有涉及变更前次股东大会决议。 一、会议召开和出席情况 证券代码：300558 证券简称：贝达药业 公告编号：2023-099 贝达药业股份有限公司（以下简称"公司"）2023 年第一次临时股东大会会 议通知于 2023 年 11 月 18 日以公告形式发出，现场会议于 2023 年 12 月 5 日（星 期二）15:00 在公司会议室召开，通过深圳证券交易所交易系统进行网络投票的具 体时间为 2023 年 12 月 5 日的交易时间，即 9:15-9:25、9:30-11:30、13:00-15:00；通 过深圳证券交易所互联网投票系统进行投票的具体时间为 2023 年 12 月 5 日 9:15- 15:00 期间的任意时间。 本次股东大会采取现场投票和网络投票相结合的方式召开。通过现场和网络 投票的股东及股东授权委托代表 87 人，代表股份 226,014,818 股，占公司股 ...

证券代码：300558 证券简称：贝达药业 公告编号：2023-098 贝达药业股份有限公司 监事会关于公司 2023 年限制性股票激励计划激励对象名单的 公示情况说明及核查意见 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 贝达药业股份有限公司（以下简称"公司"）于 2023 年 11 月 17 日召开 第四届董事会第十次会议、第四届监事会第八次会议，审议通过了《关于<贝 达药业股份有限公司 2023 年限制性股票激励计划（草案）>及其摘要的议案》 等议案 ， 具 体 内 容 详 见 公 司 于 2023 年 11 月 18 日 在 巨 潮 资 讯 网 （www.cninfo.com.cn）上披露的相关公告。 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）、 《深圳证券交易所上市公司自律监管指南第 1 号——业务办理第三部分：3.2 股权激励》（以下简称"《自律监管指南》"）的相关规定，公司对 2023 年 限制性股票激励计划（以下简称"本次激励计划"）激励对象的名单在公司内 部进行了公示，公司监事会结合公示情况对激励对象进行了核查，相关公示 ...

中信证券股份有限公司 关于贝达药业股份有限公司 使用部分闲置募集资金暂时补充流动资金的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为贝达 药业股份有限公司（以下简称"贝达药业"或"公司"）的保荐机构，根据《深 圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《上市公司监管指引第 2 号——上市公司募 集资金管理和使用的监管要求》等相关规定履行持续督导职责，对贝达药业使用 部分闲置募集资金暂时补充流动资金的事项进行了审慎核查，核查具体情况及核 查意见如下： 一、募集资金基本情况 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意贝达药业 股份有限公司向特定对象发行股票注册的批复》（证监许可[2020]2213 号）同意， 公司向 14 名特定对象发行人民币普通股（A 股）10,138,621 股，发行价格为 98.83 元/股，实际募集资金总额为人民币 1,001,999,913.43 元（大写：人民币壹拾亿零 壹佰玖拾玖万玖仟玖佰壹拾叁元肆角叁分），扣除本次发行费用（不含税）人民 币 6,594,538.73 元后， ...

证券代码：300558 证券简称：贝达药业 公告编号：2023-097 贝达药业股份有限公司 监事会关于公司 2023 年限制性股票激励计划相关事项的 核查意见 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 贝达药业股份有限公司（以下简称"公司"）监事会根据《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下 简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管理 办法》"）、《深圳证券交易所创业板股票上市规则》（以下简称"《上市规 则》"）、《深圳证券交易所创业板上市公司自律监管指南第 1 号——业务办 理》（以下简称"《自律监管指南》"）及《贝达药业股份有限公司章程》 （以下简称"《公司章程》"）的规定，对《贝达药业股份有限公司 2023 年 限制性股票激励计划（草案）》（以下简称"《激励计划（草案）》"）及其 他相关资料进行审核，发表核查意见如下： 一、监事会对《贝达药业股份有限公司 2023 年限制性股票激励计划（草 案）》及其摘要的核查意见 1、公司不存在《管理办法》规定的禁止实施股权激励计划的下列情形 ...